nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RPS6KA6—embryo—testicular cancer	0.0101	0.0229	CbGeAlD
Ruxolitinib—Myelosuppression—Vinblastine—testicular cancer	0.0086	0.0389	CcSEcCtD
Ruxolitinib—PLK3—embryo—testicular cancer	0.00845	0.0191	CbGeAlD
Ruxolitinib—CAMK1—seminal vesicle—testicular cancer	0.00742	0.0168	CbGeAlD
Ruxolitinib—Myelosuppression—Bleomycin—testicular cancer	0.00726	0.0329	CcSEcCtD
Ruxolitinib—PLK1—gonad—testicular cancer	0.00687	0.0155	CbGeAlD
Ruxolitinib—Myelosuppression—Dactinomycin—testicular cancer	0.00677	0.0306	CcSEcCtD
Ruxolitinib—ANKK1—testis—testicular cancer	0.00666	0.015	CbGeAlD
Ruxolitinib—JAK1—embryo—testicular cancer	0.00648	0.0146	CbGeAlD
Ruxolitinib—DCLK1—embryo—testicular cancer	0.00648	0.0146	CbGeAlD
Ruxolitinib—Myelosuppression—Ifosfamide—testicular cancer	0.00621	0.0281	CcSEcCtD
Ruxolitinib—JAK1—seminal vesicle—testicular cancer	0.00609	0.0137	CbGeAlD
Ruxolitinib—DAPK2—seminal vesicle—testicular cancer	0.00581	0.0131	CbGeAlD
Ruxolitinib—ROCK1—embryo—testicular cancer	0.00558	0.0126	CbGeAlD
Ruxolitinib—PRKG2—testis—testicular cancer	0.00552	0.0125	CbGeAlD
Ruxolitinib—CLK2—seminal vesicle—testicular cancer	0.00541	0.0122	CbGeAlD
Ruxolitinib—CAMK1—gonad—testicular cancer	0.00536	0.0121	CbGeAlD
Ruxolitinib—Myelosuppression—Cisplatin—testicular cancer	0.00535	0.0242	CcSEcCtD
Ruxolitinib—PRKCE—testis—testicular cancer	0.00515	0.0116	CbGeAlD
Ruxolitinib—PLK1—testis—testicular cancer	0.00495	0.0112	CbGeAlD
Ruxolitinib—RPS6KA6—testis—testicular cancer	0.00495	0.0112	CbGeAlD
Ruxolitinib—MAST1—testis—testicular cancer	0.00495	0.0112	CbGeAlD
Ruxolitinib—Myelosuppression—Etoposide—testicular cancer	0.0049	0.0222	CcSEcCtD
Ruxolitinib—NUAK2—seminal vesicle—testicular cancer	0.00487	0.011	CbGeAlD
Ruxolitinib—DCLK3—testis—testicular cancer	0.00469	0.0106	CbGeAlD
Ruxolitinib—PLK3—female gonad—testicular cancer	0.00466	0.0105	CbGeAlD
Ruxolitinib—LRRK2—seminal vesicle—testicular cancer	0.00452	0.0102	CbGeAlD
Ruxolitinib—JAK1—gonad—testicular cancer	0.0044	0.00993	CbGeAlD
Ruxolitinib—PLK4—gonad—testicular cancer	0.00437	0.00987	CbGeAlD
Ruxolitinib—CAMK1—female gonad—testicular cancer	0.00436	0.00984	CbGeAlD
Ruxolitinib—PHKG2—gonad—testicular cancer	0.00427	0.00964	CbGeAlD
Ruxolitinib—Bone pain—Vinblastine—testicular cancer	0.00421	0.019	CcSEcCtD
Ruxolitinib—PLK3—testis—testicular cancer	0.00413	0.00933	CbGeAlD
Ruxolitinib—RET—embryo—testicular cancer	0.00412	0.00932	CbGeAlD
Ruxolitinib—HIPK2—gonad—testicular cancer	0.00411	0.00927	CbGeAlD
Ruxolitinib—MAP3K7—seminal vesicle—testicular cancer	0.0041	0.00926	CbGeAlD
Ruxolitinib—TYK2—seminal vesicle—testicular cancer	0.00402	0.00909	CbGeAlD
Ruxolitinib—LTK—testis—testicular cancer	0.00399	0.00901	CbGeAlD
Ruxolitinib—MKNK2—seminal vesicle—testicular cancer	0.00397	0.00897	CbGeAlD
Ruxolitinib—TAOK2—female gonad—testicular cancer	0.00391	0.00884	CbGeAlD
Ruxolitinib—CLK2—gonad—testicular cancer	0.00391	0.00883	CbGeAlD
Ruxolitinib—JAK2—embryo—testicular cancer	0.0039	0.0088	CbGeAlD
Ruxolitinib—Herpes zoster—Ifosfamide—testicular cancer	0.00387	0.0175	CcSEcCtD
Ruxolitinib—CAMK1—testis—testicular cancer	0.00386	0.00873	CbGeAlD
Ruxolitinib—ROCK1—gonad—testicular cancer	0.00379	0.00855	CbGeAlD
Ruxolitinib—MARK2—testis—testicular cancer	0.00375	0.00847	CbGeAlD
Ruxolitinib—PRKCE—lymph node—testicular cancer	0.00374	0.00844	CbGeAlD
Ruxolitinib—DYRK1A—gonad—testicular cancer	0.00369	0.00834	CbGeAlD
Ruxolitinib—JAK2—seminal vesicle—testicular cancer	0.00366	0.00827	CbGeAlD
Ruxolitinib—JAK3—female gonad—testicular cancer	0.0036	0.00812	CbGeAlD
Ruxolitinib—PLK1—lymph node—testicular cancer	0.00359	0.00811	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—testicular cancer	0.00359	0.00811	CbGeAlD
Ruxolitinib—JAK1—female gonad—testicular cancer	0.00357	0.00807	CbGeAlD
Ruxolitinib—MAP3K3—seminal vesicle—testicular cancer	0.00353	0.00797	CbGeAlD
Ruxolitinib—CAMK1D—female gonad—testicular cancer	0.00349	0.00788	CbGeAlD
Ruxolitinib—TAOK2—testis—testicular cancer	0.00347	0.00784	CbGeAlD
Ruxolitinib—PHKG2—female gonad—testicular cancer	0.00347	0.00783	CbGeAlD
Ruxolitinib—DAPK2—female gonad—testicular cancer	0.00341	0.0077	CbGeAlD
Ruxolitinib—STK16—female gonad—testicular cancer	0.00335	0.00758	CbGeAlD
Ruxolitinib—HIPK2—female gonad—testicular cancer	0.00334	0.00754	CbGeAlD
Ruxolitinib—BMP2K—gonad—testicular cancer	0.00329	0.00744	CbGeAlD
Ruxolitinib—LRRK2—gonad—testicular cancer	0.00326	0.00737	CbGeAlD
Ruxolitinib—TAOK3—seminal vesicle—testicular cancer	0.00322	0.00727	CbGeAlD
Ruxolitinib—DAPK3—female gonad—testicular cancer	0.00321	0.00724	CbGeAlD
Ruxolitinib—JAK3—testis—testicular cancer	0.00319	0.00721	CbGeAlD
Ruxolitinib—CLK2—female gonad—testicular cancer	0.00318	0.00717	CbGeAlD
Ruxolitinib—JAK1—testis—testicular cancer	0.00317	0.00716	CbGeAlD
Ruxolitinib—DCLK1—testis—testicular cancer	0.00317	0.00716	CbGeAlD
Ruxolitinib—PLK4—testis—testicular cancer	0.00315	0.00712	CbGeAlD
Ruxolitinib—CAMK1D—testis—testicular cancer	0.00309	0.00699	CbGeAlD
Ruxolitinib—ROCK1—female gonad—testicular cancer	0.00308	0.00695	CbGeAlD
Ruxolitinib—PHKG2—testis—testicular cancer	0.00308	0.00695	CbGeAlD
Ruxolitinib—Infection—Carboplatin—testicular cancer	0.00303	0.0137	CcSEcCtD
Ruxolitinib—DAPK2—testis—testicular cancer	0.00302	0.00683	CbGeAlD
Ruxolitinib—DYRK1A—female gonad—testicular cancer	0.003	0.00678	CbGeAlD
Ruxolitinib—PLK3—lymph node—testicular cancer	0.003	0.00676	CbGeAlD
Ruxolitinib—BMPR2—female gonad—testicular cancer	0.00299	0.00675	CbGeAlD
Ruxolitinib—MAP3K2—gonad—testicular cancer	0.00299	0.00675	CbGeAlD
Ruxolitinib—STK16—testis—testicular cancer	0.00298	0.00672	CbGeAlD
Ruxolitinib—HIPK2—testis—testicular cancer	0.00296	0.00668	CbGeAlD
Ruxolitinib—MAP3K19—testis—testicular cancer	0.0029	0.00655	CbGeAlD
Ruxolitinib—LTK—lymph node—testicular cancer	0.00289	0.00653	CbGeAlD
Ruxolitinib—MKNK2—gonad—testicular cancer	0.00287	0.00648	CbGeAlD
Ruxolitinib—NUAK2—female gonad—testicular cancer	0.00286	0.00645	CbGeAlD
Ruxolitinib—DAPK3—testis—testicular cancer	0.00284	0.00642	CbGeAlD
Ruxolitinib—CLK2—testis—testicular cancer	0.00282	0.00636	CbGeAlD
Ruxolitinib—CAMK1—lymph node—testicular cancer	0.0028	0.00633	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—testicular cancer	0.00275	0.0124	CcSEcCtD
Ruxolitinib—ROCK1—testis—testicular cancer	0.00273	0.00617	CbGeAlD
Ruxolitinib—MARK2—lymph node—testicular cancer	0.00272	0.00614	CbGeAlD
Ruxolitinib—BMP2K—female gonad—testicular cancer	0.00268	0.00604	CbGeAlD
Ruxolitinib—CAMK2G—female gonad—testicular cancer	0.00268	0.00604	CbGeAlD
Ruxolitinib—DYRK1A—testis—testicular cancer	0.00266	0.00601	CbGeAlD
Ruxolitinib—BMPR2—testis—testicular cancer	0.00265	0.00599	CbGeAlD
Ruxolitinib—LRRK2—female gonad—testicular cancer	0.00265	0.00599	CbGeAlD
Ruxolitinib—JAK2—gonad—testicular cancer	0.00265	0.00598	CbGeAlD
Ruxolitinib—Pancytopenia—Chlorambucil—testicular cancer	0.00262	0.0119	CcSEcCtD
Ruxolitinib—Neutropenia—Chlorambucil—testicular cancer	0.00258	0.0117	CcSEcCtD
Ruxolitinib—MAP3K3—gonad—testicular cancer	0.00255	0.00576	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—testicular cancer	0.00254	0.0115	CcSEcCtD
Ruxolitinib—NUAK2—testis—testicular cancer	0.00253	0.00572	CbGeAlD
Ruxolitinib—TAOK2—lymph node—testicular cancer	0.00252	0.00568	CbGeAlD
Ruxolitinib—MAP3K2—female gonad—testicular cancer	0.00243	0.00549	CbGeAlD
Ruxolitinib—Body temperature increased—Carboplatin—testicular cancer	0.00241	0.0109	CcSEcCtD
Ruxolitinib—MAP3K7—female gonad—testicular cancer	0.00241	0.00544	CbGeAlD
Ruxolitinib—Pancytopenia—Vinblastine—testicular cancer	0.0024	0.0109	CcSEcCtD
Ruxolitinib—BMP2K—testis—testicular cancer	0.00237	0.00536	CbGeAlD
Ruxolitinib—CAMK2G—testis—testicular cancer	0.00237	0.00536	CbGeAlD
Ruxolitinib—TYK2—female gonad—testicular cancer	0.00236	0.00534	CbGeAlD
Ruxolitinib—LRRK2—testis—testicular cancer	0.00235	0.00531	CbGeAlD
Ruxolitinib—MKNK2—female gonad—testicular cancer	0.00233	0.00527	CbGeAlD
Ruxolitinib—IRAK1—female gonad—testicular cancer	0.00233	0.00527	CbGeAlD
Ruxolitinib—JAK3—lymph node—testicular cancer	0.00231	0.00522	CbGeAlD
Ruxolitinib—JAK1—lymph node—testicular cancer	0.0023	0.00519	CbGeAlD
Ruxolitinib—DCLK1—lymph node—testicular cancer	0.0023	0.00519	CbGeAlD
Ruxolitinib—PLK4—lymph node—testicular cancer	0.00228	0.00516	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—testicular cancer	0.00224	0.00507	CbGeAlD
Ruxolitinib—PHKG2—lymph node—testicular cancer	0.00223	0.00504	CbGeAlD
Ruxolitinib—DAPK2—lymph node—testicular cancer	0.00219	0.00495	CbGeAlD
Ruxolitinib—STK16—lymph node—testicular cancer	0.00216	0.00487	CbGeAlD
Ruxolitinib—MAP3K2—testis—testicular cancer	0.00215	0.00487	CbGeAlD
Ruxolitinib—JAK2—female gonad—testicular cancer	0.00215	0.00486	CbGeAlD
Ruxolitinib—HIPK2—lymph node—testicular cancer	0.00215	0.00485	CbGeAlD
Ruxolitinib—MAP3K7—testis—testicular cancer	0.00213	0.00482	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Ifosfamide—testicular cancer	0.00211	0.00956	CcSEcCtD
Ruxolitinib—TYK2—testis—testicular cancer	0.0021	0.00473	CbGeAlD
Ruxolitinib—MAP3K3—female gonad—testicular cancer	0.00207	0.00468	CbGeAlD
Ruxolitinib—MKNK2—testis—testicular cancer	0.00207	0.00467	CbGeAlD
Ruxolitinib—IRAK1—testis—testicular cancer	0.00207	0.00467	CbGeAlD
Ruxolitinib—DAPK3—lymph node—testicular cancer	0.00206	0.00466	CbGeAlD
Ruxolitinib—CLK2—lymph node—testicular cancer	0.00204	0.00461	CbGeAlD
Ruxolitinib—Haemoglobin—Vinblastine—testicular cancer	0.00204	0.00921	CcSEcCtD
Ruxolitinib—Pancytopenia—Bleomycin—testicular cancer	0.00203	0.00918	CcSEcCtD
Ruxolitinib—Haemorrhage—Vinblastine—testicular cancer	0.00202	0.00916	CcSEcCtD
Ruxolitinib—RET—testis—testicular cancer	0.00202	0.00456	CbGeAlD
Ruxolitinib—Weight decreased—Bleomycin—testicular cancer	0.00193	0.00874	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—testicular cancer	0.00193	0.00436	CbGeAlD
Ruxolitinib—BMPR2—lymph node—testicular cancer	0.00192	0.00434	CbGeAlD
Ruxolitinib—JAK2—testis—testicular cancer	0.00191	0.00431	CbGeAlD
Ruxolitinib—Pancytopenia—Dactinomycin—testicular cancer	0.00189	0.00856	CcSEcCtD
Ruxolitinib—TAOK3—female gonad—testicular cancer	0.00189	0.00427	CbGeAlD
Ruxolitinib—Neutropenia—Dactinomycin—testicular cancer	0.00186	0.00843	CcSEcCtD
Ruxolitinib—MAP3K3—testis—testicular cancer	0.00184	0.00415	CbGeAlD
Ruxolitinib—NUAK2—lymph node—testicular cancer	0.00184	0.00415	CbGeAlD
Ruxolitinib—Herpes zoster—Methotrexate—testicular cancer	0.00183	0.00827	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Cisplatin—testicular cancer	0.00182	0.00824	CcSEcCtD
Ruxolitinib—Haematuria—Bleomycin—testicular cancer	0.00182	0.00822	CcSEcCtD
Ruxolitinib—Anaemia—Chlorambucil—testicular cancer	0.00178	0.00804	CcSEcCtD
Ruxolitinib—Pancytopenia—Ifosfamide—testicular cancer	0.00173	0.00784	CcSEcCtD
Ruxolitinib—BMP2K—lymph node—testicular cancer	0.00172	0.00389	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—testicular cancer	0.00172	0.00389	CbGeAlD
Ruxolitinib—Haemoglobin—Bleomycin—testicular cancer	0.00172	0.00778	CcSEcCtD
Ruxolitinib—Herpes zoster—Epirubicin—testicular cancer	0.00171	0.00774	CcSEcCtD
Ruxolitinib—Haemorrhage—Bleomycin—testicular cancer	0.00171	0.00774	CcSEcCtD
Ruxolitinib—LRRK2—lymph node—testicular cancer	0.0017	0.00385	CbGeAlD
Ruxolitinib—TAOK3—testis—testicular cancer	0.00168	0.00379	CbGeAlD
Ruxolitinib—Anaemia—Vinblastine—testicular cancer	0.00163	0.00737	CcSEcCtD
Ruxolitinib—Infestation NOS—Ifosfamide—testicular cancer	0.00163	0.00737	CcSEcCtD
Ruxolitinib—Infestation—Ifosfamide—testicular cancer	0.00163	0.00737	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—testicular cancer	0.00158	0.00716	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—testicular cancer	0.00156	0.00353	CbGeAlD
Ruxolitinib—Infection—Chlorambucil—testicular cancer	0.00156	0.00706	CcSEcCtD
Ruxolitinib—Haematuria—Ifosfamide—testicular cancer	0.00155	0.00702	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—testicular cancer	0.00155	0.00349	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Ifosfamide—testicular cancer	0.00154	0.00697	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Chlorambucil—testicular cancer	0.00154	0.00695	CcSEcCtD
Ruxolitinib—TYK2—lymph node—testicular cancer	0.00152	0.00343	CbGeAlD
Ruxolitinib—IRAK1—lymph node—testicular cancer	0.0015	0.00339	CbGeAlD
Ruxolitinib—MKNK2—lymph node—testicular cancer	0.0015	0.00339	CbGeAlD
Ruxolitinib—Pancytopenia—Cisplatin—testicular cancer	0.00149	0.00676	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—testicular cancer	0.00147	0.00666	CcSEcCtD
Ruxolitinib—Haemoglobin—Ifosfamide—testicular cancer	0.00147	0.00665	CcSEcCtD
Ruxolitinib—RET—lymph node—testicular cancer	0.00146	0.0033	CbGeAlD
Ruxolitinib—Haemorrhage—Ifosfamide—testicular cancer	0.00146	0.00661	CcSEcCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—testicular cancer	0.00144	0.0875	CbGdCrCtD
Ruxolitinib—PLK1—Teniposide—Etoposide—testicular cancer	0.00144	0.0875	CbGdCrCtD
Ruxolitinib—Thrombocytopenia—Vinblastine—testicular cancer	0.00141	0.00637	CcSEcCtD
Ruxolitinib—JAK2—lymph node—testicular cancer	0.00138	0.00312	CbGeAlD
Ruxolitinib—Anaemia—Bleomycin—testicular cancer	0.00138	0.00622	CcSEcCtD
Ruxolitinib—Pancytopenia—Etoposide—testicular cancer	0.00137	0.0062	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00136	0.00613	CcSEcCtD
Ruxolitinib—Fatigue—Chlorambucil—testicular cancer	0.00135	0.00612	CcSEcCtD
Ruxolitinib—Neutropenia—Etoposide—testicular cancer	0.00135	0.0061	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—testicular cancer	0.00135	0.00609	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—testicular cancer	0.00133	0.00301	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Cisplatin—testicular cancer	0.00133	0.00601	CcSEcCtD
Ruxolitinib—Infestation NOS—Etoposide—testicular cancer	0.00129	0.00582	CcSEcCtD
Ruxolitinib—Infestation—Etoposide—testicular cancer	0.00129	0.00582	CcSEcCtD
Ruxolitinib—Anaemia—Dactinomycin—testicular cancer	0.00128	0.00581	CcSEcCtD
Ruxolitinib—Malnutrition—Ifosfamide—testicular cancer	0.00127	0.00576	CcSEcCtD
Ruxolitinib—Bone pain—Doxorubicin—testicular cancer	0.00124	0.00563	CcSEcCtD
Ruxolitinib—Body temperature increased—Chlorambucil—testicular cancer	0.00124	0.00561	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Etoposide—testicular cancer	0.00122	0.0055	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—testicular cancer	0.00121	0.00274	CbGeAlD
Ruxolitinib—Infection—Bleomycin—testicular cancer	0.00121	0.00546	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Bleomycin—testicular cancer	0.00119	0.00538	CcSEcCtD
Ruxolitinib—Anaemia—Ifosfamide—testicular cancer	0.00118	0.00532	CcSEcCtD
Ruxolitinib—Asthenia—Chlorambucil—testicular cancer	0.00113	0.0051	CcSEcCtD
Ruxolitinib—Infection—Dactinomycin—testicular cancer	0.00113	0.00509	CcSEcCtD
Ruxolitinib—Pruritus—Chlorambucil—testicular cancer	0.00111	0.00502	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dactinomycin—testicular cancer	0.00111	0.00502	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—testicular cancer	0.0011	0.0668	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—testicular cancer	0.0011	0.0668	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—testicular cancer	0.0011	0.0668	CbGdCrCtD
Ruxolitinib—Malnutrition—Cisplatin—testicular cancer	0.0011	0.00496	CcSEcCtD
Ruxolitinib—Flatulence—Cisplatin—testicular cancer	0.00108	0.00489	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00108	0.00487	CcSEcCtD
Ruxolitinib—Asthenia—Vinblastine—testicular cancer	0.00103	0.00467	CcSEcCtD
Ruxolitinib—Infection—Ifosfamide—testicular cancer	0.00103	0.00467	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—testicular cancer	0.00102	0.0618	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—testicular cancer	0.00102	0.0618	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—testicular cancer	0.00102	0.0618	CbGdCrCtD
Ruxolitinib—Nervous system disorder—Ifosfamide—testicular cancer	0.00102	0.00461	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Ifosfamide—testicular cancer	0.00102	0.0046	CcSEcCtD
Ruxolitinib—Anaemia—Cisplatin—testicular cancer	0.00101	0.00459	CcSEcCtD
Ruxolitinib—Skin disorder—Ifosfamide—testicular cancer	0.00101	0.00456	CcSEcCtD
Ruxolitinib—Fatigue—Dactinomycin—testicular cancer	0.000977	0.00442	CcSEcCtD
Ruxolitinib—Body temperature increased—Bleomycin—testicular cancer	0.00096	0.00435	CcSEcCtD
Ruxolitinib—Dizziness—Vinblastine—testicular cancer	0.000951	0.0043	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—testicular cancer	0.000935	0.00423	CcSEcCtD
Ruxolitinib—Anaemia—Etoposide—testicular cancer	0.000929	0.0042	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000927	0.0042	CcSEcCtD
Ruxolitinib—Headache—Vinblastine—testicular cancer	0.000901	0.00408	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000896	0.00406	CcSEcCtD
Ruxolitinib—Body temperature increased—Dactinomycin—testicular cancer	0.000896	0.00405	CcSEcCtD
Ruxolitinib—Fatigue—Ifosfamide—testicular cancer	0.000895	0.00405	CcSEcCtD
Ruxolitinib—Infection—Cisplatin—testicular cancer	0.000889	0.00402	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cisplatin—testicular cancer	0.000878	0.00397	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cisplatin—testicular cancer	0.000876	0.00397	CcSEcCtD
Ruxolitinib—Asthenia—Bleomycin—testicular cancer	0.000872	0.00394	CcSEcCtD
Ruxolitinib—Skin disorder—Cisplatin—testicular cancer	0.00087	0.00393	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.000865	0.00392	CcSEcCtD
Ruxolitinib—Pruritus—Bleomycin—testicular cancer	0.00086	0.00389	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00085	0.00384	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000825	0.00373	CcSEcCtD
Ruxolitinib—Body temperature increased—Ifosfamide—testicular cancer	0.000821	0.00371	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—testicular cancer	0.00082	0.00371	CcSEcCtD
Ruxolitinib—Infection—Etoposide—testicular cancer	0.000815	0.00369	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—testicular cancer	0.000813	0.00368	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—testicular cancer	0.000808	0.00365	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Etoposide—testicular cancer	0.000803	0.00363	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—testicular cancer	0.000797	0.0036	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000773	0.0035	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—testicular cancer	0.00077	0.00348	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—testicular cancer	0.00077	0.00348	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—testicular cancer	0.000768	0.00347	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000763	0.00345	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—testicular cancer	0.000756	0.00342	CcSEcCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—testicular cancer	0.000753	0.0456	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—testicular cancer	0.000753	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—testicular cancer	0.000753	0.0456	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—testicular cancer	0.000753	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—testicular cancer	0.000753	0.0456	CbGdCrCtD
Ruxolitinib—Asthenia—Ifosfamide—testicular cancer	0.000745	0.00337	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—testicular cancer	0.000736	0.00333	CcSEcCtD
Ruxolitinib—Pruritus—Ifosfamide—testicular cancer	0.000735	0.00332	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—testicular cancer	0.000734	0.00332	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—testicular cancer	0.000731	0.00331	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—testicular cancer	0.000728	0.0033	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—testicular cancer	0.000726	0.00329	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—testicular cancer	0.000721	0.00326	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—testicular cancer	0.000721	0.00326	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—testicular cancer	0.00071	0.00321	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000708	0.0032	CcSEcCtD
Ruxolitinib—Body temperature increased—Cisplatin—testicular cancer	0.000708	0.0032	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—testicular cancer	0.000707	0.0032	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—testicular cancer	0.000701	0.00317	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—testicular cancer	0.000699	0.00316	CcSEcCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—testicular cancer	0.000696	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—testicular cancer	0.000696	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—testicular cancer	0.000696	0.0422	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—testicular cancer	0.000696	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—testicular cancer	0.000696	0.0422	CbGdCrCtD
Ruxolitinib—Haemoglobin—Methotrexate—testicular cancer	0.000695	0.00314	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—testicular cancer	0.000691	0.00313	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—testicular cancer	0.000687	0.00311	CcSEcCtD
Ruxolitinib—Dizziness—Ifosfamide—testicular cancer	0.000687	0.00311	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—testicular cancer	0.000682	0.00308	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—testicular cancer	0.000681	0.00308	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—testicular cancer	0.00068	0.00308	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—testicular cancer	0.000677	0.00306	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—testicular cancer	0.000667	0.00302	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—testicular cancer	0.000667	0.00302	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—testicular cancer	0.00065	0.00294	CcSEcCtD
Ruxolitinib—Body temperature increased—Etoposide—testicular cancer	0.000648	0.00293	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—testicular cancer	0.000648	0.00293	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—testicular cancer	0.000647	0.00293	CcSEcCtD
Ruxolitinib—Asthenia—Cisplatin—testicular cancer	0.000642	0.00291	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—testicular cancer	0.000636	0.00288	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000631	0.00285	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—testicular cancer	0.000629	0.00285	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—testicular cancer	0.000602	0.00272	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—testicular cancer	0.000602	0.00272	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—testicular cancer	0.000599	0.00271	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—testicular cancer	0.000588	0.00266	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—testicular cancer	0.00058	0.00262	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—testicular cancer	0.000563	0.00255	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—testicular cancer	0.000556	0.00252	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—testicular cancer	0.000555	0.00251	CcSEcCtD
Ruxolitinib—Dizziness—Etoposide—testicular cancer	0.000542	0.00245	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—testicular cancer	0.000521	0.00236	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—testicular cancer	0.000521	0.00236	CcSEcCtD
Ruxolitinib—Headache—Etoposide—testicular cancer	0.000514	0.00232	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—testicular cancer	0.000514	0.00232	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000509	0.0023	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—testicular cancer	0.000488	0.00221	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—testicular cancer	0.000482	0.00218	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—testicular cancer	0.000482	0.00218	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—testicular cancer	0.000481	0.00218	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—testicular cancer	0.000477	0.00216	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000476	0.00215	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—testicular cancer	0.000457	0.00207	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—testicular cancer	0.000451	0.00204	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—testicular cancer	0.00045	0.00204	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—testicular cancer	0.000447	0.00202	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000441	0.00199	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000424	0.00192	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—testicular cancer	0.000424	0.00192	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—testicular cancer	0.000423	0.00191	CcSEcCtD
Ruxolitinib—HIPK2—Gene Expression—H2AFZ—testicular cancer	0.000421	0.00132	CbGpPWpGaD
Ruxolitinib—Nervous system disorder—Doxorubicin—testicular cancer	0.000417	0.00189	CcSEcCtD
Ruxolitinib—JAK1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000417	0.0013	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by SCF-KIT—KIT—testicular cancer	0.000417	0.0013	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—KITLG—testicular cancer	0.000417	0.0013	CbGpPWpGaD
Ruxolitinib—Thrombocytopenia—Doxorubicin—testicular cancer	0.000416	0.00188	CcSEcCtD
Ruxolitinib—JAK2—Signaling by FGFR—KITLG—testicular cancer	0.000415	0.0013	CbGpPWpGaD
Ruxolitinib—Skin disorder—Doxorubicin—testicular cancer	0.000413	0.00187	CcSEcCtD
Ruxolitinib—JAK2—Signaling by ERBB2—KITLG—testicular cancer	0.000412	0.00129	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—KITLG—testicular cancer	0.00041	0.00128	CbGpPWpGaD
Ruxolitinib—TYK2—Downstream signal transduction—FGFR3—testicular cancer	0.000409	0.00128	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR—FGFR3—testicular cancer	0.000407	0.00127	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by ERBB2—FGFR3—testicular cancer	0.000405	0.00127	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 signaling—FGFR3—testicular cancer	0.000403	0.00126	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000402	0.00126	CbGpPWpGaD
Ruxolitinib—TYK2—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000399	0.00125	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—INSL3—testicular cancer	0.000399	0.00125	CbGpPWpGaD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000397	0.0018	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—testicular cancer	0.000396	0.00179	CcSEcCtD
Ruxolitinib—TYK2—Signaling by ERBB4—KIT—testicular cancer	0.000393	0.00123	CbGpPWpGaD
Ruxolitinib—Body temperature increased—Methotrexate—testicular cancer	0.000388	0.00176	CcSEcCtD
Ruxolitinib—JAK2—Signaling by FGFR in disease—KITLG—testicular cancer	0.000386	0.00121	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—KITLG—testicular cancer	0.000386	0.00121	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000386	0.00121	CbGpPWpGaD
Ruxolitinib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000385	0.0012	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—KITLG—testicular cancer	0.000383	0.0012	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—HPGDS—testicular cancer	0.000381	0.00119	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000379	0.00119	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—FGFR3—testicular cancer	0.000379	0.00118	CbGpPWpGaD
Ruxolitinib—TYK2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000379	0.00118	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000379	0.00118	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—KITLG—testicular cancer	0.000378	0.00118	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR—FGFR3—testicular cancer	0.000375	0.00117	CbGpPWpGaD
Ruxolitinib—TYK2—Downstream signal transduction—KIT—testicular cancer	0.000375	0.00117	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR—KIT—testicular cancer	0.000373	0.00117	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000372	0.00116	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by ERBB2—KIT—testicular cancer	0.000371	0.00116	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by PDGF—FGFR3—testicular cancer	0.00037	0.00116	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 signaling—KIT—testicular cancer	0.00037	0.00116	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—KITLG—testicular cancer	0.000369	0.00116	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—H2AFZ—testicular cancer	0.000368	0.00115	CbGpPWpGaD
Ruxolitinib—MAP3K7—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000367	0.00115	CbGpPWpGaD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000367	0.00166	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—testicular cancer	0.000367	0.00166	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—testicular cancer	0.000363	0.00164	CcSEcCtD
Ruxolitinib—JAK2—GPCR downstream signaling—INSL3—testicular cancer	0.000358	0.00112	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—KITLG—testicular cancer	0.000358	0.00112	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—BCL10—testicular cancer	0.000357	0.00112	CbGpPWpGaD
Ruxolitinib—JAK2—Chromatin modifying enzymes—H2AFZ—testicular cancer	0.000357	0.00112	CbGpPWpGaD
Ruxolitinib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000353	0.00111	CbGpPWpGaD
Ruxolitinib—Asthenia—Methotrexate—testicular cancer	0.000352	0.00159	CcSEcCtD
Ruxolitinib—JAK1—Signaling by NGF—FGFR3—testicular cancer	0.000349	0.00109	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—KIT—testicular cancer	0.000348	0.00109	CbGpPWpGaD
Ruxolitinib—TYK2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000348	0.00109	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR in disease—KIT—testicular cancer	0.000348	0.00109	CbGpPWpGaD
Ruxolitinib—Pruritus—Methotrexate—testicular cancer	0.000348	0.00157	CcSEcCtD
Ruxolitinib—TYK2—Signaling by NGF—KITLG—testicular cancer	0.000347	0.00109	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR—KIT—testicular cancer	0.000345	0.00108	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000344	0.00108	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—INSL3—testicular cancer	0.000343	0.00107	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000342	0.00107	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000342	0.00107	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by PDGF—KIT—testicular cancer	0.00034	0.00106	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—FGFR3—testicular cancer	0.00034	0.00106	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—KITLG—testicular cancer	0.000338	0.00106	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—BCL10—testicular cancer	0.000338	0.00106	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—INSL3—testicular cancer	0.000337	0.00106	CbGpPWpGaD
Ruxolitinib—MAP3K7—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000337	0.00105	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling by Wnt—H2AFZ—testicular cancer	0.000337	0.00105	CbGpPWpGaD
Ruxolitinib—Body temperature increased—Doxorubicin—testicular cancer	0.000336	0.00152	CcSEcCtD
Ruxolitinib—TYK2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000335	0.00105	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—H2AFZ—testicular cancer	0.000333	0.00104	CbGpPWpGaD
Ruxolitinib—Asthenia—Epirubicin—testicular cancer	0.00033	0.00149	CcSEcCtD
Ruxolitinib—JAK2—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000329	0.00103	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—BCL10—testicular cancer	0.000328	0.00103	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—BCL10—testicular cancer	0.000327	0.00102	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—STK11—testicular cancer	0.000326	0.00102	CbGpPWpGaD
Ruxolitinib—Pruritus—Epirubicin—testicular cancer	0.000325	0.00147	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—testicular cancer	0.000325	0.00147	CcSEcCtD
Ruxolitinib—JAK2—Signaling by GPCR—INSL3—testicular cancer	0.000325	0.00102	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB4—FGFR3—testicular cancer	0.000324	0.00101	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by NGF—KIT—testicular cancer	0.000321	0.001	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—BCL10—testicular cancer	0.000319	0.000998	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—BCL10—testicular cancer	0.000318	0.000996	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by SCF-KIT—KIT—testicular cancer	0.000316	0.000989	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—KIT—testicular cancer	0.000312	0.000976	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—FGFR3—testicular cancer	0.00031	0.000968	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—FGFR3—testicular cancer	0.000308	0.000964	CbGpPWpGaD
Ruxolitinib—TYK2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000308	0.000963	CbGpPWpGaD
Ruxolitinib—Headache—Methotrexate—testicular cancer	0.000308	0.00139	CcSEcCtD
Ruxolitinib—JAK2—Signaling by ERBB2—FGFR3—testicular cancer	0.000307	0.000959	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—KITLG—testicular cancer	0.000306	0.000957	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—BCL10—testicular cancer	0.000306	0.000956	CbGpPWpGaD
Ruxolitinib—Asthenia—Doxorubicin—testicular cancer	0.000305	0.00138	CcSEcCtD
Ruxolitinib—JAK2—DAP12 signaling—FGFR3—testicular cancer	0.000305	0.000954	CbGpPWpGaD
Ruxolitinib—Dizziness—Epirubicin—testicular cancer	0.000304	0.00138	CcSEcCtD
Ruxolitinib—JAK2—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000302	0.000946	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—BCL10—testicular cancer	0.000301	0.000942	CbGpPWpGaD
Ruxolitinib—Pruritus—Doxorubicin—testicular cancer	0.000301	0.00136	CcSEcCtD
Ruxolitinib—JAK2—Signaling by ERBB4—KIT—testicular cancer	0.000298	0.000931	CbGpPWpGaD
Ruxolitinib—Headache—Epirubicin—testicular cancer	0.000288	0.0013	CcSEcCtD
Ruxolitinib—JAK2—DAP12 interactions—FGFR3—testicular cancer	0.000287	0.000898	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000287	0.000898	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000287	0.000898	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—FGFR3—testicular cancer	0.000284	0.00089	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—KIT—testicular cancer	0.000284	0.000889	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—KIT—testicular cancer	0.000283	0.000885	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000282	0.000882	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB2—KIT—testicular cancer	0.000281	0.00088	CbGpPWpGaD
Ruxolitinib—Dizziness—Doxorubicin—testicular cancer	0.000281	0.00127	CcSEcCtD
Ruxolitinib—JAK2—Signaling by PDGF—FGFR3—testicular cancer	0.000281	0.000878	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—KIT—testicular cancer	0.00028	0.000876	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—STK11—testicular cancer	0.000277	0.000866	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—FGFR3—testicular cancer	0.000275	0.000859	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—H2AFZ—testicular cancer	0.000274	0.000857	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—STK11—testicular cancer	0.000272	0.000852	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—KITLG—testicular cancer	0.000268	0.000839	CbGpPWpGaD
Ruxolitinib—Headache—Doxorubicin—testicular cancer	0.000266	0.00121	CcSEcCtD
Ruxolitinib—IRAK1—Signaling by NGF—FGFR3—testicular cancer	0.000266	0.000831	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000264	0.000824	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—KIT—testicular cancer	0.000264	0.000824	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—KIT—testicular cancer	0.000264	0.000824	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—KITLG—testicular cancer	0.000263	0.000823	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—KIT—testicular cancer	0.000261	0.000817	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—INSL3—testicular cancer	0.000261	0.000816	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—BCL10—testicular cancer	0.000259	0.00081	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000259	0.00081	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—FGFR3—testicular cancer	0.000258	0.000807	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—KIT—testicular cancer	0.000258	0.000806	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—H2AFZ—testicular cancer	0.000258	0.000805	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—MMP2—testicular cancer	0.000257	0.000805	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—STK11—testicular cancer	0.000256	0.000801	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000254	0.000795	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—INSL3—testicular cancer	0.000253	0.000792	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—MMP2—testicular cancer	0.000253	0.000792	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—KIT—testicular cancer	0.000252	0.000788	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—KITLG—testicular cancer	0.000252	0.000788	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—FGFR3—testicular cancer	0.000251	0.000786	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—BCL10—testicular cancer	0.000249	0.000778	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INSL3—testicular cancer	0.000246	0.000768	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—KIT—testicular cancer	0.000244	0.000763	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—KITLG—testicular cancer	0.000237	0.000741	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—KIT—testicular cancer	0.000237	0.000741	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000233	0.00073	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—H2AFZ—testicular cancer	0.000233	0.000728	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—STK11—testicular cancer	0.000232	0.000724	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—KIT—testicular cancer	0.000231	0.000722	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—FGFR3—testicular cancer	0.000227	0.000711	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—H2AFZ—testicular cancer	0.000216	0.000675	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KITLG—testicular cancer	0.000215	0.000673	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KITLG—testicular cancer	0.000214	0.00067	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—KIT—testicular cancer	0.000209	0.000653	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KITLG—testicular cancer	0.000204	0.000638	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—FGFR3—testicular cancer	0.000199	0.000623	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KITLG—testicular cancer	0.000199	0.000621	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KITLG—testicular cancer	0.000198	0.000619	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KITLG—testicular cancer	0.000197	0.000616	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BCL10—testicular cancer	0.000197	0.000616	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—FGFR3—testicular cancer	0.000196	0.000612	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KITLG—testicular cancer	0.000192	0.000602	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KITLG—testicular cancer	0.000192	0.000601	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INSL3—testicular cancer	0.000192	0.0006	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BCL10—testicular cancer	0.000191	0.000598	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—MMP2—testicular cancer	0.00019	0.000594	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—FGFR3—testicular cancer	0.000187	0.000586	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BCL10—testicular cancer	0.000185	0.00058	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KITLG—testicular cancer	0.000184	0.000577	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—MMP2—testicular cancer	0.000184	0.000574	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—KIT—testicular cancer	0.000183	0.000572	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KITLG—testicular cancer	0.000182	0.000568	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—MMP2—testicular cancer	0.000181	0.000565	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—KIT—testicular cancer	0.00018	0.000561	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—FGFR3—testicular cancer	0.000176	0.000551	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—KIT—testicular cancer	0.000172	0.000538	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000166	0.00052	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—KIT—testicular cancer	0.000162	0.000506	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—FGFR3—testicular cancer	0.00016	0.0005	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—FGFR3—testicular cancer	0.000159	0.000498	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—H2AFZ—testicular cancer	0.000157	0.00049	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KITLG—testicular cancer	0.000156	0.000489	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—FGFR3—testicular cancer	0.000152	0.000474	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—H2AFZ—testicular cancer	0.000151	0.000473	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—STK11—testicular cancer	0.00015	0.00047	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KITLG—testicular cancer	0.00015	0.000469	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—FGFR3—testicular cancer	0.000148	0.000462	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—FGFR3—testicular cancer	0.000147	0.00046	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KIT—testicular cancer	0.000147	0.000459	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—FGFR3—testicular cancer	0.000146	0.000458	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KIT—testicular cancer	0.000146	0.000457	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL10—testicular cancer	0.000145	0.000453	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KITLG—testicular cancer	0.000144	0.000451	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—MMP2—testicular cancer	0.000144	0.00045	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—FGFR3—testicular cancer	0.000143	0.000447	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—FGFR3—testicular cancer	0.000143	0.000446	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KIT—testicular cancer	0.000139	0.000435	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KITLG—testicular cancer	0.000139	0.000435	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—FGFR3—testicular cancer	0.000137	0.000429	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MMP2—testicular cancer	0.000136	0.000424	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KIT—testicular cancer	0.000136	0.000424	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KIT—testicular cancer	0.000135	0.000423	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—FGFR3—testicular cancer	0.000135	0.000422	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KIT—testicular cancer	0.000134	0.000421	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KIT—testicular cancer	0.000131	0.000411	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KIT—testicular cancer	0.000131	0.00041	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—H2AFZ—testicular cancer	0.000128	0.000399	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STK11—testicular cancer	0.000127	0.000397	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KIT—testicular cancer	0.000126	0.000394	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KIT—testicular cancer	0.000124	0.000388	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KITLG—testicular cancer	0.000119	0.000372	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KITLG—testicular cancer	0.000117	0.000367	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—FGFR3—testicular cancer	0.000116	0.000363	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—H2AFZ—testicular cancer	0.000116	0.000362	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KITLG—testicular cancer	0.000115	0.000361	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KITLG—testicular cancer	0.000112	0.00035	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—FGFR3—testicular cancer	0.000112	0.000349	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—H2AFZ—testicular cancer	0.00011	0.000343	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STK11—testicular cancer	0.000109	0.000341	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—H2AFZ—testicular cancer	0.000108	0.000338	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STK11—testicular cancer	0.000107	0.000336	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—FGFR3—testicular cancer	0.000107	0.000335	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KIT—testicular cancer	0.000107	0.000333	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KITLG—testicular cancer	0.000106	0.000333	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—FGFR3—testicular cancer	0.000103	0.000323	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP2—testicular cancer	0.000103	0.000321	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KIT—testicular cancer	0.000102	0.00032	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KITLG—testicular cancer	0.000101	0.000316	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KITLG—testicular cancer	9.93e-05	0.000311	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KIT—testicular cancer	9.84e-05	0.000308	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KIT—testicular cancer	9.49e-05	0.000297	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—FGFR3—testicular cancer	8.83e-05	0.000276	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—H2AFZ—testicular cancer	8.77e-05	0.000274	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KITLG—testicular cancer	8.74e-05	0.000273	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—FGFR3—testicular cancer	8.72e-05	0.000273	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—FGFR3—testicular cancer	8.57e-05	0.000268	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—H2AFZ—testicular cancer	8.35e-05	0.000261	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—FGFR3—testicular cancer	8.31e-05	0.00026	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STK11—testicular cancer	8.3e-05	0.00026	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KIT—testicular cancer	8.11e-05	0.000254	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—H2AFZ—testicular cancer	8.1e-05	0.000253	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KITLG—testicular cancer	8.07e-05	0.000252	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STK11—testicular cancer	8.06e-05	0.000252	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KIT—testicular cancer	8.01e-05	0.000251	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—FGFR3—testicular cancer	7.91e-05	0.000247	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KIT—testicular cancer	7.87e-05	0.000246	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—H2AFZ—testicular cancer	7.86e-05	0.000246	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STK11—testicular cancer	7.81e-05	0.000244	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KITLG—testicular cancer	7.68e-05	0.00024	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KIT—testicular cancer	7.63e-05	0.000239	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—FGFR3—testicular cancer	7.51e-05	0.000235	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KITLG—testicular cancer	7.46e-05	0.000233	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—FGFR3—testicular cancer	7.38e-05	0.000231	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KIT—testicular cancer	7.26e-05	0.000227	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KITLG—testicular cancer	7.23e-05	0.000226	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KIT—testicular cancer	6.89e-05	0.000216	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KIT—testicular cancer	6.78e-05	0.000212	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FGFR3—testicular cancer	6.49e-05	0.000203	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—H2AFZ—testicular cancer	6.14e-05	0.000192	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STK11—testicular cancer	6.11e-05	0.000191	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FGFR3—testicular cancer	6e-05	0.000188	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KIT—testicular cancer	5.96e-05	0.000187	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGFR3—testicular cancer	5.71e-05	0.000179	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KITLG—testicular cancer	5.65e-05	0.000177	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGFR3—testicular cancer	5.54e-05	0.000173	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KIT—testicular cancer	5.51e-05	0.000172	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGFR3—testicular cancer	5.37e-05	0.000168	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KIT—testicular cancer	5.24e-05	0.000164	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KIT—testicular cancer	5.09e-05	0.000159	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KIT—testicular cancer	4.93e-05	0.000154	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGFR3—testicular cancer	4.2e-05	0.000131	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—testicular cancer	3.86e-05	0.000121	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HPGDS—testicular cancer	2.84e-05	8.89e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STK11—testicular cancer	2.06e-05	6.46e-05	CbGpPWpGaD
